Dear Editors, Human T cell leukemia virus type I (HTLV-I) is a human retrovirus that is an etiologic agent of adult T cell leukemia/lymphoma (ATL/ATLL) [1] . Adult ATL/ATLL is an aggressive lymphoid neoplasm associated with HTLV-1 [2] . The CC-chemokine receptor 4 (CCR4) is expressed in almost all ATLL cells [3, 4] . Thus, anti-CCR4 antibodies can be used as a treatment strategy for ATLL. Mogamulizumab (MOG), which is a defucosylated anti-CCR4 monoclonal antibody, showed good results even in patients with recurrent ATLL in phase I or II studies [5, 6] . In a phase II study of MOG for ATLL, the overall response rate was 50 % and progression-free survival and overall survival were also significantly improved [5] . The common adverse events in the phase II study were infusion reaction and skin rashes, which were manageable and reversible [6] . In the present study, we treated four elderly patients with ATL who were resistant to chemotherapy using MOG monotherapy, and we observed CCR4-specific ADCC against CCR4-positive ATL cells. All patients showed complete remission (CR) with a marked decrease in the number of ATL cells. Characteristics of those patients were summarized in Table 1 . In this study, cytomegalovirus (CMV) infection was detected in two patients using C7-horseradish peroxidase (C7-HRP) methods. One of the two patients died because of severe CMV infection despite adequate treatment. Case 2 involved a 64-year-old man whose condition was diagnosed as chronic ATL 5 years back. Thereafter, the number of ATL cells in the peripheral blood and serum sIL2-R level increased gradually. Furthermore, the diagnosis of transformation of his condition to acute type ATL was made. He received THP-COP regimen every 2 weeks for 6 cycles. However, the number of ATL cells in the peripheral blood rapidly increased significantly. The patient was positive for tax gene, and his serum proviral DNA level was 740 copies/1,000 cells after six courses of the THP-COP regimen. The CCR4 expression level was 94 %. He received an intravenous injection of 1.0 mg/kg of MOG every week for eight courses. Subsequently, the number of ATL cells in the peripheral blood and serum sIL2-R levels decreased rapidly. After three courses of treatment with MOG, no rearrangement for T cell receptor (TCR) αβ chain in the peripheral blood was detected. He achieved molecular CR. However, after a few courses of treatment, the number of lymphocytes in the peripheral blood decreased markedly. After four courses of treatment, he was positive for C7-HRP, which is indicative of CMV infection. Ganciclovir (GCV) was administered. He had disturbance of consciousness, and his condition was diagnosed as CMV encephalitis. He received GCV again, but the CMV infection was not resolved. He died because of the uncontrollable CMV infection. The fourth case involved a 73-year-old woman with acute ATL. ATL cells accounted for 36 % of white blood cells in the peripheral blood. The CCR4 expression level was 68.6 %. She received an intravenous injection of 1.0 mg/kg of MOG every week. The ATL cells in the peripheral blood Y.
Dear Editors, Human T cell leukemia virus type I (HTLV-I) is a human retrovirus that is an etiologic agent of adult T cell leukemia/lymphoma (ATL/ATLL) [1] . Adult ATL/ATLL is an aggressive lymphoid neoplasm associated with HTLV-1 [2] . The CC-chemokine receptor 4 (CCR4) is expressed in almost all ATLL cells [3, 4] . Thus, anti-CCR4 antibodies can be used as a treatment strategy for ATLL. Mogamulizumab (MOG), which is a defucosylated anti-CCR4 monoclonal antibody, showed good results even in patients with recurrent ATLL in phase I or II studies [5, 6] . In a phase II study of MOG for ATLL, the overall response rate was 50 % and progression-free survival and overall survival were also significantly improved [5] . The common adverse events in the phase II study were infusion reaction and skin rashes, which were manageable and reversible [6] . In the present study, we treated four elderly patients with ATL who were resistant to chemotherapy using MOG monotherapy, and we observed CCR4-specific ADCC against CCR4-positive ATL cells. All patients showed complete remission (CR) with a marked decrease in the number of ATL cells. Characteristics of those patients were summarized in Table 1 . In this study, cytomegalovirus (CMV) infection was detected in two patients using C7-horseradish peroxidase (C7-HRP) methods. One of the two patients died because of severe CMV infection despite adequate treatment. Case 2 involved a 64-year-old man whose condition was diagnosed as chronic ATL 5 years back. Thereafter, the number of ATL cells in the peripheral blood and serum sIL2-R level increased gradually. Furthermore, the diagnosis of transformation of his condition to acute type ATL was made. He received THP-COP regimen every 2 weeks for 6 cycles. However, the number of ATL cells in the peripheral blood rapidly increased significantly. The patient was positive for tax gene, and his serum proviral DNA level was 740 copies/1,000 cells after six courses of the THP-COP regimen. The CCR4 expression level was 94 %. He received an intravenous injection of 1.0 mg/kg of MOG every week for eight courses. Subsequently, the number of ATL cells in the peripheral blood and serum sIL2-R levels decreased rapidly. After three courses of treatment with MOG, no rearrangement for T cell receptor (TCR) αβ chain in the peripheral blood was detected. He achieved molecular CR. However, after a few courses of treatment, the number of lymphocytes in the peripheral blood decreased markedly. After four courses of treatment, he was positive for C7-HRP, which is indicative of CMV infection. Ganciclovir (GCV) was administered. He had disturbance of consciousness, and his condition was diagnosed as CMV encephalitis. He received GCV again, but the CMV infection was not resolved. He died because of the uncontrollable CMV infection. The fourth case involved a 73-year-old woman with acute ATL. ATL cells accounted for 36 % of white blood cells in the peripheral blood. The CCR4 expression level was 68.6 %. She received an intravenous injection of 1.0 mg/kg of MOG every week. The ATL cells in the peripheral blood disappeared after two courses, and rearrangement of TCR αβ vanished after three courses. She achieved CR without severe adverse events until three courses. However, after four courses of treatment with MOG, she had skin rash throughout her body. Despite taking 30 mg/day of prednisolone, no improvement in skin rash was observed. After five courses of treatment with MOG, the skin rash spread throughout her body with bulla. Skin biopsy was performed, and her condition was diagnosed as Stevens-Johnson syndrome (SJS). Administration of steroid and intravenous immunoglobulin was performed, and SJS gradually improved. ATL cells were not found in her peripheral blood, and no rearrangement of TCR αβ gene was observed, which indicated molecular CR. However, CMV infection was observed several times during her clinical course. Population of CD4 + 25 + T lymphocytes, which was confirmed as Treg, decreased after treatment with MOG. Thus, viral infection, including CMV infection, may occur after MOG therapy. These results suggested that MOG was effective in chemotherapy-resistant ATL patients. However, CCR4 is not only on ATL cells but also on endogenous Treg [7, 8] . The decrease in the number of Treg after MOG monotherapy has been expected to boost the antitumor activity and to be involved in the development of immune disorders, including autoimmune diseases. Furthermore, a decrease in CD4 + T cells led to viral infection. In particular, active CMV infection is associated with a rapid decrease in CD4 + T cells in human immunodeficiency virus infection [9] . In this study, CMV infection was detected in two patients using C7-HRP methods. One of the two patients died because of severe CMV infection. Thus, physicians should be aware of CMV infection and development of immunocompromised condition after MOG monotherapy. Specific anti-CMV treatment for CMV reactivation should be recommended. To our knowledge, no studies have reported the correlation between active CMV infection and blunted CD4 + T cells. Human CMV infection establishes lifelong persistence after primary infection. To identify the risk factor for CMV infection in autoimmune disease, 106 patients with autoimmune disease was reported [10] . Results of a multivariate analysis showed that lymphopenia, systemic lupus erythematosus, and polymyositis/dermatomyositis were significantly associated with increased viral load of CMV [10] . Chronic CMV infection is associated with intermittent viral reactivation, including high frequencies of CD4 + T lymphocytes [11] . Furthermore, CMV infection is associated with the exhaustion of CMV-specific CD4 + T cells, which have low functional avidity of viral antigen [11] . However, CMV-specific CD4 + T cells may not be induced in ATL patients after MOG therapy because of the immunocompromised condition of the patients. In conclusion, several treatments for prophylaxis of opportunistic infection, including CMV infection, should be recommended. 
